Biotechs Back To “New Normal,” E&Y Reports
This article was originally published in The Pink Sheet Daily
Executive Summary
The annual report issued by Ernst & Young shows that biotech funding and revenues are back to relatively normal levels after a few years of pullback, but 2011 could be a transitional year.
You may also be interested in...
On Building A Better R&D Machine, Part 2: Pfizer’s R&D Chief Mikael Dolsten Talks Partnering Strategy And Accessing Innovation
Since ascending to the top R&D spot at the world’s largest pharmaceutical company, Mikael Dolsten has taken the lead in focusing R&D at Pfizer and optimizing its portfolio. In the second of a two-part interview with "The Pink Sheet" DAILY, Dolsten shares his thoughts on partnering and accessing external opportunities.
Biotechs Need To Be More Differentiated To Succeed, E&Y Reports
The 25th annual Ernst & Young report shows that biotechs have fewer exit strategies than ever and that pre-clinical stage companies still have a hard time finding financing.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.